Ray Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its lead candidate, RTx-015, marking a key regulatory milestone for the company’s optogenetic approach to vision restoration.
The designation applies to RTx-015 for the treatment of retinitis pigmentosa (RP). RMAT status is granted to therapies targeting serious conditions where early clinical evidence suggests the potential to address significant unmet need, and it enables closer interaction with the FDA alongside potential pathways to accelerated development and review.
RTx-015 is an optogenetic gene therapy designed to restore visual function by delivering a bioengineered, highly light-sensitive protein to targeted retinal cells. Unlike mutation-specific gene therapies, the approach is intended to work independently of the underlying genetic cause of disease – potentially broadening its applicability across the heterogeneous RP population.
The therapy is administered as a single intravitreal injection and aims to reprogramme remaining retinal cells to respond to light, effectively bypassing degenerated photoreceptors. This represents a shift from conventional strategies focused on slowing disease progression toward actively restoring functional vision in patients with advanced disease.
According to the company, the RMAT designation will support more efficient clinical development as RTx-015 advances toward late-stage trials. Ray Therapeutics indicated that future studies will prioritize endpoints reflecting real-world visual function and quality of life – an important consideration in a condition where traditional measures may not fully capture patient benefit.
Beyond RP, the company is developing a broader pipeline of optogenetic therapies. Its second clinical-stage candidate, RTx-021, is targeting macular diseases including Stargardt disease and geographic atrophy, with a focus on retinal bipolar cells.
The RMAT designation underscores growing momentum in regenerative and gene-based approaches within ophthalmology, particularly for conditions with limited treatment options. For clinicians, optogenetics represents an emerging modality that could complement – or potentially extend beyond – existing gene therapies by offering mutation-agnostic solutions for retinal degeneration.
While clinical efficacy data for RTx-015 are still evolving, the regulatory recognition highlights its potential as a novel therapeutic strategy in RP, a field where restoring vision remains a significant unmet goal.
Source: Ray Therapeutics.
